Brevan Howard Capital Management’s Cytokinetics CYTK Stock Holding History

Brevan Howard Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	11,891 -37,070	-76%	-$2.66M	0.01%	1050
2026 Q1	$3.23M	Sell	48,961 -52,069	-52%	-$3.31M	0.03%	384
2025 Q4	$6.42M	Buy	101,030 +91,056	+913%	+$5.66M	0.07%	182
2025 Q3	$548K	Buy	+9,974	New	+$411K	﹤0.01%	1246
2025 Q1	–	Sell	-8,976	Closed	-$422K	–	1218
2024 Q4	$422K	Buy	+8,976	New	+$466K	﹤0.01%	669
2024 Q2	–	Sell	-14,990	Closed	-$1.05M	–	1121
2024 Q1	$1.05M	Buy	14,990 +6,924	+86%	+$536K	0.01%	250
2023 Q4	$673K	Buy	+8,066	New	+$292K	0.01%	369

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's CYTK Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Cytokinetics (CYTK) stake by 76% in Q2 2026, selling an estimated $2.66M and leaving 11,891 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1050.

Brevan Howard Capital Management first reported a position in CYTK in Q4 2023 and has held it in 7 quarters since. The position peaked at $6.42M in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Brevan Howard Capital Management held 11,891 shares of Cytokinetics worth $1.01M as of Q2 2026.
Brevan Howard Capital Management sold 37,070 Cytokinetics shares in Q2 2026, an estimated $2.66M.
Cytokinetics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1050 holding.
Brevan Howard Capital Management first reported a position in Cytokinetics in Q4 2023 and has held it in 7 quarters since.
Brevan Howard Capital Management's Cytokinetics position peaked at $6.42M in Q4 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.